Major cancer research findings unveiled at 2026 AACR meeting
2026年美國癌症研究協會（AACR）年會發表重大癌症研究成果
The 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego marked a significant leap forward in oncology.
2026年於聖地牙哥舉行的美國癌症研究協會（AACR）年會標誌著腫瘤學的重大飛躍。
With over 22,000 experts gathering, the focus remained on precision, partnership, and purpose.
超過2萬2千名專家齊聚一堂，聚焦於精準醫療、合作與目標。
A primary highlight was the study of Early-Onset Colorectal Cancer (EOCRC), where researchers utilized Artificial Intelligence to discover that these tumors operate in a more immunosuppressive environment than late-onset cases.
其中一項主要亮點是對早發型大腸癌（EOCRC）的研究，研究人員利用人工智慧發現這些腫瘤處於比晚發型病例更具免疫抑制的環境中。
Furthermore, advancements in immunotherapy revealed how the NAT10-MYC pathway contributes to drug resistance, offering new targets for treatment.
此外，免疫治療的進展揭示了NAT10-MYC路徑如何導致耐藥性，為治療提供了新的標靶。
In clinical applications, the antibody-drug conjugate trastuzumab deruxtecan demonstrated superior survival outcomes for specific metastatic cancers compared to traditional chemotherapy.
在臨床應用方面，抗體藥物偶聯體（ADC）trastuzumab deruxtecan相較於傳統化學治療，對特定轉移性癌症展現出更優越的存活率。
The conference also emphasized the integration of AI tools, such as the OncoTwin framework for predicting treatment responses in lung cancer.
會議還強調了AI工具的整合，例如用於預測肺癌治療反應的OncoTwin架構。
Finally, researchers explored how age-related changes in the immune system necessitate more tailored treatment strategies for older patients.
最後，研究人員探討了年齡相關的免疫系統變化如何需要為高齡患者制定更量身訂做的治療策略。
